

## Santen Announces Completion of Share Buyback and Number of Shares to be Canceled

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito, hereinafter “the Company”) announced the completion of the share buyback as stated below. The share buyback was implemented in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3.

The Company is scheduled to cancel all the amount of shares repurchased on March 31, 2023, based on the Notice of “Santen Announces Cancellation of Treasury Shares” dated March 22, 2023.

### 1. Share buyback status as of March 24, 2023

- |  |   |
|--|---|
| (1) Class of shares repurchased        | : Common shares   |
| (2) Total number of shares repurchased | : 1,248,100 shares  |
| (3) Total amount of repurchase         | : 1,332,579,800 yen   |
| (4) Period of repurchase               | : March 1, 2023 to March 24, 2023<br>(execution date basis)     |
| (5) Method of repurchase               | : Open-market repurchase by the<br>discretionary trading method |

### 2. Total Company's own shares repurchased through March 24, 2023 pursuant to the resolution at the Board of Directors meeting held on November 8, 2022

- |  |                      |
|--|----------------------|
| (1) Total number of shares repurchased | : 12,369,700 shares  |
| (2) Total amount of repurchase         | : 12,999,887,400 yen |

### 3. Total Company's own shares to be canceled pursuant to the resolution at the Board of Directors meeting held on March 22, 2023

- |   |   |
|---|---|
| (1) Class of shares to be canceled        | : Common shares   |
| (2) Total number of shares to be canceled | : 12,369,700 shares<br>(The ratio against total number of the<br>outstanding shares before the Cancellation:<br>3.2%) |
| (3) Scheduled date of cancellation        | : March 31, 2023  |
- The total number of the outstanding shares of the Company (including its treasury shares) after the Cancellation is expected to be 375,885,854 shares.
  - The number of treasury shares after the Cancellation is expected to be 303,156 shares.

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on November 8, 2022)

- |  |  |
|--|--|
| (1) Class of shares to be repurchased        | : Common shares  |
| (2) Total number of shares to be repurchased | : 13,000,000 shares (maximum)  |
|  | *Representing 3.4% of the total number of shares outstanding (excluding treasury shares) |
| (3) Total amount of repurchase               | : 13.0 billion yen (maximum)   |
| (4) Period of repurchase                     | : November 9, 2022 to March 24, 2023   |

**Contact:**

Guillaume Sakuma

Global Head of IR, IR Group

E-mail: [ir@santen.com](mailto:ir@santen.com)

**About Santen**

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en>).